{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:17:04Z","timestamp":1788556624860,"version":"build-2803163510"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>After a long hiatus, psychiatry is undergoing a resurgence of interest in psychedelic drugs as therapy for a wide range of mental health disorders Accumulating clinical evidence suggests substantial potential for psychedelics used in a therapeutic context, as treatment for, among other disorders, depression, post-traumatic stress disorder (PTSD), and addictions to tobacco, opioids and alcohol. As soon as 2024, powerful new therapeutic modalities could become available for individuals with mental health problems refractory to traditional therapies. Yet research has lagged on economic considerations, such as costs and cost-effectiveness, the economic effects of widespread implementation, pricing, and economic appraisal's methodological considerations relevant to psychedelic therapies. These issues are critical if psychedelic therapies are to become widely accessible. We describe six types of economic analyses and their rationale for decisions and planning including the needs of health care payers. We also outline desirable features of this research, including scientific rigor, long horizons, equity, and a global view.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.1025726","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:01:43Z","timestamp":1670198503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["The economics of psychedelic-assisted therapies: A research agenda"],"prefix":"10.3389","volume":"13","author":[{"given":"Elliot","family":"Marseille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet."},{"key":"B2","unstructured":"SaloniD HannahR RoserM Mental Health"},{"key":"B3","unstructured":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Harbi","year":"2012","journal-title":"Patient Prefer Adherence."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/PPA.S110632","article-title":"Long-term antidepressant use: patient perspectives of benefits and adverse effects","volume":"10","author":"Cartwright","year":"2016","journal-title":"Patient Prefer Adherence."},{"key":"B6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.mehy.2011.01.020","article-title":"Tardive dysphoria: the role of long term antidepressant use in-inducing chronic depression","volume":"76","author":"El-Mallakh","year":"2011","journal-title":"Med Hypotheses."},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/YCT.0000000000000137","article-title":"Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy","volume":"30","author":"Mcclintock","year":"2014","journal-title":"J ECT."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1192\/bjo.2020.17","volume":"59","author":"Verwijk","year":"2017","journal-title":"Tijdschr Psychiatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.sbspro.2010.07.435","article-title":"Effectiveness of psychotherapy for adults with depression: a systematic review of the best available evidence","volume":"5","author":"Berg","year":"2010","journal-title":"Procedia Soc Behav Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1600-0447.2007.01007.x","article-title":"Treating depression with the evidence-based psychotherapies: a critique of the evidence","volume":"115","author":"Parker","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"Cd003388","DOI":"10.1002\/14651858.CD003388.pub4","article-title":"Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults","volume":"2013","author":"Bisson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1037\/tra0000062","article-title":"Time course of treatment dropout in cognitive-behavioral therapies for posttraumatic stress disorder","volume":"8","author":"Gutner","year":"2016","journal-title":"Psychol Trauma."},{"key":"B15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnbeh.2018.00258","article-title":"Treating PTSD: a review of evidence-based psychotherapy interventions","volume":"12","author":"Watkins","year":"2018","journal-title":"Front Behav Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illnessimplications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7812\/TPP\/17-024","article-title":"Urgent need for improved mental health care and a more collaborative model of care","volume":"21","author":"Lake","year":"2017","journal-title":"Perm J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2017","journal-title":"Psychopharmacology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D'Souza","year":"2022","journal-title":"Neuropsychopharmacology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12888-019-2288-z","article-title":"Serotonergic hallucinogens\/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer","volume":"19","author":"Dos Santos","year":"2019","journal-title":"BMC Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","author":"Mitchell","year":"2021","journal-title":"Nature Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs. placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J Psychopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr Scand."},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry's brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J Psychoactive Drugs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"07067437221111371","DOI":"10.1177\/07067437221111371","article-title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder","author":"Rosenblat","year":"2022","journal-title":"Can J Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"14116","DOI":"10.4088\/JCP.21m14116","volume":"83","author":"Davis","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B40","author":"Drummond","year":"1997","journal-title":"Methods for the Economic Evaluation of Health Care Programmes."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","author":"Gold","year":"1996","journal-title":"Cost-effectiveness in Health and MEDICINe"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"key":"B43","doi-asserted-by":"publisher","first-page":"116715","DOI":"10.1016\/j.jns.2020.116715","article-title":"A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses","volume":"411","author":"Chi","year":"2020","journal-title":"J Neurol Sci."},{"key":"B44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2020","journal-title":"JAMA Psychiatry."},{"key":"B46","author":"Johnson","year":"2022","journal-title":"SYM5-2: Psilocybin-Facilitated Smoking Cessation: Comparative Efficacy vs. Nicotine Patch"},{"key":"B47","doi-asserted-by":"publisher","first-page":"103473","DOI":"10.1016\/j.drugpo.2021.103473","article-title":"United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020","volume":"99","author":"Barnett","year":"2022","journal-title":"Int J Drug Policy."},{"key":"B48","unstructured":"2021"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01122-0","article-title":"The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: a modeling study","author":"Avancena","year":"2022","journal-title":"Clin Drug Investig."},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","author":"Drummond","year":"2005","journal-title":"Methods for the Economic Evaluation of Health Care Programmes (Third Edition)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1524-4733.2001.43040.x","article-title":"Health economic guidelines\u2014similarities, differences and some implications","volume":"4","author":"Hjelmgren","year":"2001","journal-title":"Value Health."},{"key":"B52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0168-8510(00)00076-2","article-title":"The influence of economic evaluation studies on decision making. a European survey. The EUROMET group","volume":"52","author":"Hoffmann","year":"2000","journal-title":"Health Policy."},{"key":"B53","year":"2004","journal-title":"Guide to Technology Appraisal Process"},{"key":"B54","unstructured":"2019"},{"key":"B55","year":"2014","journal-title":"Guide to the Methods of Technology Apprisal 2013"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e220320","DOI":"10.1001\/jamanetworkopen.2022.0320","article-title":"Trends in disenrollment and reenrollment within US commercial health insurance plans, 2006-2018","volume":"5","author":"Fang","year":"2022","journal-title":"JAMA Network Open."},{"key":"B57","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0269881118771782","article-title":"Psychedelic use and intimate partner violence: the role of emotion regulation","volume":"32","author":"Thiessen","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0263252","DOI":"10.1371\/journal.pone.0263252","article-title":"Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: findings from a phase 3 trial","volume":"17","author":"Marseille","year":"2022","journal-title":"PLoS ONE."},{"key":"B61","unstructured":"PathwaysCOMPASS,. COMP360 Psilocybin Therapy for Treatment-Resistant Depression: Phase IIb Topline Data. 2021"},{"key":"B62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/09540260701563320","article-title":"Clinical trials: bridging the gap between efficacy and effectiveness","volume":"19","author":"Depp","year":"2007","journal-title":"Int Rev Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0277-9536(94)00353-U","article-title":"The relationship between cost-effectiveness analysis and cost-benefit analysis","volume":"41","author":"Johannesson","year":"1995","journal-title":"Soc Sci Med."},{"key":"B64","year":"2021","journal-title":"Psychedelic Landscape Report"},{"key":"B65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/02791072.2021.1957183","article-title":"Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey","volume":"54","author":"Barnett","year":"2022","journal-title":"J Psychoactive Drugs."},{"key":"B66","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","article-title":"Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States","volume":"54","author":"Davis","year":"2022","journal-title":"J Psychoactive Drugs."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","article-title":"Psychedelic perceptions: mental health service user attitudes to psilocybin therapy","volume":"191","author":"Corrigan","year":"2022","journal-title":"Ir J Med Sci."},{"key":"B68","author":"Newswire","year":"2022","journal-title":"Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD"},{"key":"B69","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/cer-2021-0226","article-title":"US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation\/behavior","volume":"11","author":"Voelker","year":"2022","journal-title":"J Comp Eff Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrd1633","article-title":"Pricing medicines: theory and practice, challenges and opportunities","volume":"4","author":"Gregson","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/hec.3801","article-title":"Price elasticities of pharmaceuticals in a value based-formulary setting","volume":"27","author":"Yeung","year":"2018","journal-title":"Health Econ."},{"key":"B72","unstructured":"2022"},{"key":"B73","unstructured":"2022"},{"key":"B74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: a systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci Biobehav Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"831092","DOI":"10.3389\/fpsyt.2022.831092","article-title":"Effects of naturalistic psychedelic use on depression, anxiety, and well-being: associations with patterns of use, reported harms, and transformative mental states","volume":"13","author":"Raison","year":"2022","journal-title":"Front Psychiatry."},{"key":"B76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/02698811211008554","article-title":"Psychedelics and health behaviour change","volume":"36","author":"Teixeira","year":"2022","journal-title":"J Psychopharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.cpr.2010.03.005","article-title":"Gratitude and well-being: a review and theoretical integration","volume":"30","author":"Wood","year":"2010","journal-title":"Clin Psychol Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/17439760.2021.2016910","article-title":"The emotional state assessment tool: a brief, philosophically informed, and cross-culturally sensitive measure","volume":"17","author":"Yaden","year":"2022","journal-title":"J Posit Psychol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S1744133107004355","article-title":"Developing methods that really do value the \u2018Q' in the QALY","volume":"3","author":"Dolan","year":"2008","journal-title":"Health Economics, Policy Law."},{"key":"B80","unstructured":"2022"},{"key":"B81","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2989\/16085906.2019.1680398","article-title":"Developing the global health cost consortium unit cost study repository for HIV and TB: methodology and lessons learned","volume":"18","author":"DeCormier Plosky","year":"2019","journal-title":"Afr J AIDS Res."},{"key":"B82","unstructured":"VassallA SweeneyS KahnJG GomezGB BollingerL MarseilleELSE Reference Case for Estimating the Costs of Global Health Services and Intervention2017"},{"key":"B83","unstructured":"2021"},{"key":"B84","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ije\/dyu038","article-title":"The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013","volume":"43","author":"Steel","year":"2014","journal-title":"Int J Epidemiol."},{"key":"B85","unstructured":"Population, Total. World Bank2020"},{"key":"B86","unstructured":"2021"},{"key":"B87","unstructured":"Psychedelic Landscape Report2021"},{"key":"B88","unstructured":"FY 2019-2020 Financial Report2022"},{"key":"B89","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jama.2021.12481","article-title":"Two models of legalization of psychedelic substances: reasons for concern","volume":"326","author":"Smith","year":"2021","journal-title":"JAMA."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: polishing alice's looking glass [perspective]","volume":"11","author":"Petranker","year":"2020","journal-title":"Front Psychol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1025726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T07:57:14Z","timestamp":1701503834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1025726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":90,"alternative-id":["10.3389\/fpsyt.2022.1025726"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1025726","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"article-number":"1025726"}}